文献速递关节外科

初次全髋关节置换术中停用脂质体布比卡因不改变术后主观疼痛、阿片消耗或客观功能状态

Discontinuation of Intraoperative Liposomal Bupivacaine in Primary THA Does Not Clinically Change Postoperative Subjective Pain, Opioid Consumption, or Objective Functional Status.
PubMed 文献 · J Arthroplasty · 2021-01-28

该研究比较了初次全髋关节置换术中停用脂质体布比卡因(LB)关节周围注射(PAI)前后连续队列的术后结局。结果显示,停用LB后主观疼痛评分在12-24小时和36-48小时有轻微统计学升高,但阿片消耗和AM-PAC功能评分无差异,结论认为无临床意义。

要点

  • 停用LB PAI后疼痛评分轻微升高但无临床意义
  • 阿片消耗和AM-PAC功能评分在停用LB后无变化
  • 初次THA术中LB PAI的常规使用价值有限

核心结论

  • 停用LB PAI后主观疼痛评分有轻微统计学差异但无临床意义,阿片消耗和功能评分无变化。

主要发现

  • 非LB组BMI更高(30.06 vs 29.43;P < .05),其余基线人口学除婚姻状态外相似(P > .05)。
  • 非LB组疼痛评分在12-24小时(4.42 ± 1.70 vs 4.20 ± 1.87;P < .05)和36-48小时(4.49 ± 1.72 vs 4.21 ± 1.83;P < .05)轻微升高。
  • 术后96小时内住院阿片给药无差异(P > .05),术后24小时内AM-PAC功能评分无差异(P > .05)。

临床怎么用

  • 在初次THA中可考虑停用LB PAI而不影响阿片消耗和早期功能恢复。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is debate regarding the benefit of liposomal bupivacaine (LB) as part of a periarticular injection (PAI) in total hip arthroplasty (THA). Here, we evaluate the effect of discontinuing intraoperative LB PAI on immediate postoperative subjective pain, opioid consumption, and objective functional outcomes. METHODS: On July 1, 2019, an institutional policy discontinued the use of intraoperative LB PAI. A consecutive cohort that received LB PAI and a subsequent cohort that did not were compared. All patients received the same opioid-sparing protocol. Nursing documented verbal rating scale pain scores were averaged per patient per 12-hour interval. Opiate administration events were converted into morphine milligram equivalences per patient per 24-hour interval. The validated Activity Measure for Postacute Care (AM-PAC) tool was used to evaluate functional outcomes. RESULTS: Six hundred thirty eight primary THAs received LB followed by 939 that did not. In the non-LB THAs, BMI was higher (30.06 vs 29.43; P < .05). Besides marital status, the remaining baseline demographics were similar between the two cohorts (P > .05). The non-LB THA cohort demonstrated a marginal increase in verbal rating scale pain scores between 12 to 24 hours (4.42 ± 1.70 vs 4.20 ± 1.87; P < .05) and 36 to 48 hours (4.49 ± 1.72 vs 4.21 ± 1.83; P < .05). There was no difference in inpatient opioid administration up to 96 hours postoperatively (P > .05) or AM-PAC functional scores within the first 24 hours (P > .05). CONCLUSION: A small statistical, but not clinically meaningful, difference was observed in subjective pain scores with LB PAI discontinuation. Opioid consumption and postoperative AM-PAC functional scores were unchanged after LB PAI discontinuation.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Feng JE, Ikwuazom CP, Slover JD, et al. Discontinuation of Intraoperative Liposomal Bupivacaine in Primary THA Does Not Clinically Change Postoperative Subjective Pain, Opioid Consumption, or Objective Functional Status. J Arthroplasty. 2021. PMID: 33610407. doi:10.1016/j.arth.2021.01.064

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。